
ATAI: Is Atai Beckley Inc. Halal?
Atai Beckley Inc.
$7.44
+0.81%
Market Cap: 2.8B
Compliance Status
Doubtful
Screened on Sep 2, 2026 · AAOIFI Standard 21
Good
Is Atai Beckley Inc. (ATAI) halal? Doubtful. Based on AAOIFI screening, Atai Beckley Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 72/100 (Grade: B+).
Quote this verdict
HalalScreener rates Atai Beckley Inc. (ATAI) Doubtful, 72/100, grade B+ under AAOIFI Standard 21, screened Sep 2, 2026. Source: https://halalscreener.app/en/stock/ATAI
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
What this means for you
You may own ATAI, with caution
Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.
Purification amount is Pro
We have screened ATAI's prohibited income, but the exact share you would need to purify is part of Pro.
About Atai Beckley Inc.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
Sector: Healthcare · Industry: Biotechnology
Why This Stock Is Doubtful
- Non-compliant income is 4.6% of revenue, only 0.4 points below the 5% limit
Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.
Shariah Compliance Status
Compliance History
Doubtfulnow
since Aug 2026
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Track ATAI and 6,200+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Atai Beckley Inc. (ATAI) halal to invest in?
Why did Atai Beckley Inc. get a B+ compliance rating?
What could change Atai Beckley Inc.'s Shariah verdict?
How often is Atai Beckley Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.